
    
      This study aims to evaluate and compare the pharmacokinetic (PK) profiles of abaloparatide-SC
      80 μg injected subcutaneously into the periumbilical region of the abdomen, and
      abaloparatide-sMTS 300 μg applied to the thigh for 5 minutes in a cohort of healthy men and
      to make a similar evaluation in a cohort of healthy women.
    
  